Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dermatological Medicine
Volume 2017 (2017), Article ID 2386234, 3 pages
https://doi.org/10.1155/2017/2386234
Case Report

Repigmentation of Tenacious Vitiligo on Apremilast

1University of Toledo College of Medicine and Life Sciences, 3000 Arlington Avenue, Toledo, OH 43614, USA
2Department of Dermatology, University of Toledo Medical Center, 3000 Arlington Avenue, Toledo, OH 43614, USA

Correspondence should be addressed to Sara B. Huff; ude.odelotu@eornom.aras

Received 26 July 2017; Accepted 8 October 2017; Published 6 November 2017

Academic Editor: Kowichi Jimbow

Copyright © 2017 Sara B. Huff and Lorie D. Gottwald. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. F. Mohammed, A. H. Gomaa, and M. S. Al-Dhubaibi, “Highlights in pathogenesis of vitiligo,” World Journal of Clinical Cases, vol. 3, no. 3, pp. 221–230, 2015. View at Publisher · View at Google Scholar
  2. C. K. Sharma, M. Sharma, B. Aggarwal, and V. Sharma, “Different advanced therapeutic approaches to treat vitiligo,” Journal of Environmental Pathology, Toxicology and Oncology, vol. 34, no. 4, pp. 321–334, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. J. F. Rork, M. Rashighi, and J. E. Harris, “Understanding autoimmunity of vitiligo and alopecia areata,” Current Opinion in Pediatrics, vol. 28, no. 4, pp. 463–469, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. C. M. Nguyen, K. Beroukhim, M. J. Danesh, A. Babikian, J. Koo, and A. Leon, “The psychosocial impact of acne, vitiligo, and psoriasis: A review,” Clinical, Cosmetic and Investigational Dermatology, vol. 9, pp. 383–392, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. B. S. Daniel and R. Wittal, “Vitiligo treatment update,” Australasian Journal of Dermatology, vol. 56, no. 2, pp. 85–92, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Ezzedine, V. Eleftheriadou, M. Whitton, and N. van Geel, “Vitiligo,” The Lancet, vol. 386, no. 9988, pp. 74–84, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Gilhar, A. G. Schrum, A. Etzioni, H. Waldmann, and R. Paus, “Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies,” Autoimmunity Reviews, vol. 15, no. 7, pp. 726–735, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Schafer, “Apremilast mechanism of action and application to psoriasis and psoriatic arthritis,” Biochemical Pharmacology, vol. 83, no. 12, pp. 1583–1590, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Manga, N. Elbuluk, and S. J. Orlow, “Recent advances in understanding vitiligo,” F1000Research, vol. 5, 2016. View at Google Scholar
  10. P. H. Schafer, A. Parton, L. Capone et al., “Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity,” Cellular Signalling, vol. 26, no. 9, pp. 2016–2029, 2014. View at Publisher · View at Google Scholar
  11. M. Kidir, A. A. Karabulut, M. E. Ercin, and P. Atasoy, “Regulatory T-cell cytokines in patients with nonsegmental vitiligo,” International Journal of Dermatology, vol. 56, no. 5, pp. 581–588, 2017. View at Publisher · View at Google Scholar · View at Scopus